Emese Zsiros
Roswell Park Comprehensive Cancer Center · Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emese Zsiros as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:50 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07489287 · GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube CancerRoswell Park Cancer Institute · recruiting · Platinum-resistant Ovarian Cancer · principal investigator
- N/ANCT06855706 · An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 StudyRoswell Park Cancer Institute · recruiting · Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma · principal investigator
- Ph2NCT05231122 · Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRoswell Park Cancer Institute · recruiting · Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma · principal investigator
- Ph2NCT04919629 · APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRoswell Park Cancer Institute · recruiting · Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma · principal investigator
- Ph1/Ph2NCT03735589 · Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerRoswell Park Cancer Institute · withdrawn · Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8 · principal investigator
- Ph1NCT03691376 · Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerRoswell Park Cancer Institute · terminated · Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma · principal investigator
- Ph2NCT03685695 · Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerRoswell Park Cancer Institute · completed · Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm · principal investigator
- Early Ph1NCT03297489 · Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian CancerRoswell Park Cancer Institute · completed · Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Stage I Ovarian Cancer · principal investigator
- Ph1NCT03017131 · Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerRoswell Park Cancer Institute · active not recruiting · Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma · principal investigator
- Ph2NCT02953457 · Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationRoswell Park Cancer Institute · completed · BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma · principal investigator
- Ph2NCT02853318 · Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerRoswell Park Cancer Institute · completed · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma · principal investigator
- Ph1/Ph2NCT02166905 · DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionRoswell Park Cancer Institute · completed · Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancerR01CA267690 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2022 to 2026 · $663,819 awarded in 2026Grant number is on one of their registry trials
- Network Lead Academic Participating Site Grant from the Roswell Park Cancer InstituteUG1CA233191 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2024 · $437,615 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 1P50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Pawel Kalinski · fiscal years 2013 to 2025
- Administrative CoreP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dale Henry · fiscal years 2014 to 2026Named on NCT03017131, NCT02166905
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:50 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- 192 citationsRCR 10.5
- 48 citationsRCR 24.0
- Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer.Nat Commun · 202440 citationsRCR 4.3
- A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.Nat Cancer · 202325 citationsRCR 1.6
- mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors.J Immunother Cancer · 20259 citationsRCR 1.8